Program subject to change. Please check back for updates.
Wednesday, October 24, 2018
What does FutureLab look like? What does your lab need to focus on to be ready to operate in a Clinical Lab 2.0 environment?
In this one-day interactive Summit, strategic planning experts and lab leaders will guide attendees step-by-step through the process of connecting trends to trajectories and developing a competitive roadmap for your diagnostic lab using Clinical Lab 2.0 ideology.
In the morning sessions, we’ll conduct an external scan and learn about the market oppor…
Chair, Department of Pathology and Laboratory Medicine / Senior Vice President Laboratory Services,
Zucker School of Medicine, Hofstra/Northwell / Northwell Health System
As the industry presses toward value based care and with ongoing reimbursement compression still at play, laboratories are struggling to control their destinies. They to need to take steps to mitigate lost revenue, and to develop strategies that exploit their unique advantages. Hospital vs. independent, clinical vs specialty are just two of the schisms evident in healthcare diagnostics today that are setting laboratories on divergent paths.
The movement towards value-based healthcare has provided a platform for a better future for all involved in the health ecosystem. Driven by converging forces—growing population health needs, limited resources, advances in science and data analytics—the focus on how to adapt established systems to drive better patient outcomes and improved cost efficiencies has become paramount.
However, among the multitud…
Join us for beverages and canapes as our guest. Meet the Exhibitors and network with your colleagues. There will be plenty of refreshments.
Thursday, October 25, 2018
We all know that we live in an age of disruption. But what does that mean for the labs of today? And how do laboratories not just survive, but thrive in today’s healthcare environment?
This Power Panel consists of the top laboratory leaders who have successful transition stories that we can all learn from. And they’re willing to share their stories and tactics of how they refined their business models, te…
Executive Director, Enterprise Laboratory Services, Robert J. Tomsich Pathology and Laboratory Medicine Institute,
Cleveland Clinic
Medical Director, Business Development, IT and Support Services,
ARUP Laboratories
In 2014, Theranos founder and CEO Elizabeth Holmes was widely seen as the female Steve Jobs—a brilliant Stanford dropout whose startup promised to revolutionize the medical industry with a machine that would make blood testing significantly faster and easier. Backed by investors such as Larry Ellison and Tim Draper, Theranos sold shares in a fundraising round that valued the company at more than $9 billion, putting Holmes’s worth at an estimated $4.7 b…
Pulitzer Prize-Winning Journalist & Author,
Bad Blood: Secrets and Lies in a Silicon Valley Startup
Book-signing with John Carreyrou in the Exhibitor Hall
“This is your call to be part of the Lab 2.0 Movement”
The concept of “Clinical Lab 2.0” was introduced in 2017 by Project Santa Fe, with the goal of establishing the evidence base for valuation of the clinical laboratory in the next era of American health care. In this session, lessons learned from ongoing demonstration projects will be shared, with the goal of equipping attendees to transform their own work eff…
Chair, Department of Pathology and Laboratory Medicine / Senior Vice President Laboratory Services,
Zucker School of Medicine, Hofstra/Northwell / Northwell Health System
In 2010 Ameritox settled a False Claims Act case for $16.3M and entered into a Corporate Integrity Agreement (CIA) with the Department of Health and Human Services Office of Inspector General (OIG). Andrea Treese Berlin was the attorney who handled that matter on behalf of the OIG. Barb Senters (now of Sonic Healthcare) was, thereafter, hired as the Chief Compliance Officer to administer and, ultimately, close out the CIA. One of her first steps was to invite the whistleblower, Debra Maul, to…
Senior Counsel,
United States Department of Health and Human Services, Office of the Inspector General, Office of Counsel to the Inspector General
Over the last five years, we have seen a significant increase in toxicology and genetic testing as well as Medicare and third party payor audits of these tests. It is important for those in the industry to know how to protect your laboratory from these audits and collateral consequences. This session will look at…
Owner/Principal, Wachler & Associates, PC
Medical laboratories and pathology groups face enormous levels of change in their clinical, regulatory and financial environments. With reduced reimbursement, laboratories are under increasing pressure to optimize business practices, improve utilization and cut costs while improving patient care. To meet this challenge, pathologists and lab managers know they must get better at using metrics to support the many operational decisions required to boost product…
In this presentation, Ms. Comilla will discuss the approach LTS Health used to lead the UK NHS consolidation plan, which is transferable to USA health systems. The approach was initially applied to pathology labs and has now been extended to imaging, which has started Phase 1.
This consolidation plan had three phases:
Phase 1: Workforce efficiency benchmarking
Defining, …
In this session Diana Voorhees, nationally recognized coding and billing compliance expert, will provide a close look at how to comply with the perennial lab challenges, including documenting medical necessity, test order documentation, coding changes for 2019, coverage issues and more. Plus, you’ll explore how the rules are evolving and being applied to novel billing, coding and reimbursement issues, and review critical billing and coding changes upco…
This presentation will discuss accelerating the diagnosis and treatment of cancer using digital pathology to improve efficiencies in workflow secondary consults, tumor boards, research, training, and much more.
After attending this session, participants will:
- have a clear understanding of how digital pathology speeds the diagnosis and treatment process for patients
- be able to determine if digita…
With the formation of larger health systems and integrated delivery networks across the US, the role of the laboratory and integrated laboratory data remains of critical importance. What is the best way to achieve balance in local delivery of care and optimization of testing across multiple laboratories? What is most important? Delivering high quality and excellent service? Eliminating redundancy and realizing economies of scale? Can these philosophies co-ex…
Manager, Outreach and Network Development Laboratory Medicine and Pathology,
Mayo Clinic
The bar for providing evidence to secure coverage and reimbursement for new technologies is routinely being raised. As an example, laboratories can meet the evidence requirements of Evidence Street and still not meet those of Anthem BCBS, another BCBS Association member. The varying definitions of clinical utility among health plans and third party technology assessment providers require lab companies to conduct numerous studies and publish data in multiple …
Out-of-network reimbursements remain a viable option for labs, but many struggle because they are unfamiliar with some of the intricacies required to successfully run an operation with this payment model. In fact, there are many unanswered questions that could greatly affect being aptly compensated for services they are rightfully delivering.
Learning objectives:
After attend…
How will hospital laboratories be able to provide quality laboratory service in a healthcare environment that is increasingly subject to disruptive change? With laboratory reimbursement declining to unprecedentedy low levels, how will hospital labs adapt to survive and potentially thrive? How can laboratories manage test utilization to ensure best practice care and operational efficiency? What roles do physician engagement and employee engagement play in dev…
The billing for lab services is amazing complex and nuanced; there are thousands of variables which go into the process to get paid for services. It is imperative in these times of financial crisis that labs work to audit their billing process. Mick Raich and Shreya Patel will discuss how this process is handled and teach the attendees the tenets of this process.
- Charge capture, are you billing everything you do?
- Claim review, HFCA vers…
Should a hospital outsource or sell part or all of outreach services? Does partnership or joint venture with a commercial lab make economic sense? How will PAMA affect hospital outreach laboratories? What is the true value of a hospital outreach lab? There are many correct answers, but they usually begin with “it depends”. This presentation will detail the history of financial growth in hospital laboratory outreach, the timeline for regulatory ov…
MACRA impacts pathologists’ reimbursement under Part B Medicare reimbursement. The 2018 updates to the legislation introduces changes to the existing mandate that will further impact reporting and financial adjustments. Pathologists need to understand what MACRA is and how it affects their institutions.
This session will be presented in the following parts:
- Historical overview
- MACRA as the…
Laboratory technology is growing rapidly, and with the expansion of genetic and molecular-based testing, insurance companies have fallen behind in the explosive growth. The cost of the technology is increasing more rapidly than the ability to understand and manage; as a result, health plans have reacted by cutting reimbursement, adding medical policy limitations, contracting with benefit managers, and narrowing and closing their networks to any new providers…
Learn how laboratory workflow experts execute precise cost-per-test studies as a necessary step in managing costs and eliminating unnecessary expenses. This presentation will explore the correct approach to identifying relevant cost parameters, along with proven ways to analyze the resulting data to intelligently guide cost-cutting efforts.
Attending this session, participants will:
- gain insight on how w…
The traditional “profile” of the laboratory professional is of an introvert who likes to work away from the limelight and only leave the bench or office for lunch and to go home. But this lack of visibility is damaging to our profession, leading many to either overlook or minimize the critical nature of our profession in patient care. This session will discuss why laboratorians need to break out of ou…
In March 2018, the Centers for Medicare & Medicaid Services (CMS) issued a final National Coverage Determination (NCD) for patients who receive next generation sequencing (NGS) testing with an assay that meets coverage criteria for solid tumor patients with Stage III and Stage IV, metastatic, recurrent, relapsed, or refractory cancers.
This is a major milestone in payer acceptance for NGS oncology panels.
The opioid crisis has had a huge impact in our country. Clinical laboratories are often times at the front of helping to address this crisis. In our current healthcare environment, it has become almost impossible to accomplish the goal of helping in-patient treatment because of Draconian rules in place from payors. Additionally, there are other pressures on laboratories that make it almost impossible to work effe…
Join us for beverages and canapes as our guest.
Friday, October 26, 2018
“We can’t treat our way out of the health care crisis. We must learn our way out of it.”
For most of history, health care was centered on the doctor’s office or hospital. Today, health care is much more complex. The proliferation of information available to physicians and to their patients has fundamentally shifted the focus of information and power to patients. In the information age, the evolution of learning and application of big data, analyti…
In this session, the presenters will offer perspectives about why hospitals and commercial laboratories pursue strategic partnerships; how to align business objectives and patient care needs; and key legal and compliance considerations hospitals and commercial laboratories must address in implementing strategic partnerships.
Three learning objectives:
- Learn about strategic and patient care considerations…
Chair, Department of Pathology & Laboratory Medicine,
Connecticut Health Network
Book-signing in the Exhibitor Hall with Dr. Jack Cochran.
In this role-playing session, Rick VanNess and Patty Kehoe will demonstrate the Clinical Lab 2.0 business model in action, how laboratory can be compensated outside of the traditional cost/test, deflecting the financial impact of PAMA while repositioning themselves for value-based care.
In this session, we will look at the Present Payer (insurance company)’s point of view: How do they think? How do they evaluate? What do they need? And then introduce how clinical laboratories can…
Prior authorization requirements are being implemented by the major payers for molecular and genetic tests. This session will provide insight on the impact of prior authorizations on the healthcare system, effective techniques that are helping laboratories submit more clean claims, and getting reimbursed in a timely manner all while reducing costs.
